In this interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies.
A prototype wearable device has been developed to continuously collect live cancer cells directly from a patient’s blood, presenting an alternative to biopsies.
A new microfluidics device has been developed that could detect individual cancer cells in blood and has the potential to be used for liquid biopsies.
Researchers from the University of Strathclyde (Glasgow, UK) have developed a new biomarker test that could diagnose sepsis in under 3 minutes.
Researchers have developed a new diagnostic technique to accurately differentiate bladder cancer from benign inflammation using AHNAK2 protein biomarkers.
Researchers have used mass spectrometry to analyze blister fluid in order to aid the diagnosis of burn severity.
Researchers from McMaster University (Ontario, Canada) have discovered several new biomarkers that could allow earlier detection of cystic fibrosis from a single drop of blood.
A noninvasive skin-stripping test has been developed to differentiate between eczema and psoriasis when diagnosing inflammatory skin diseases.
Thermo Fisher Scientific (MA, USA) have announced the launch of a new complementary diagnostic immunoassay, the Thermo Scientific QMS Plazomicin Immunoassay, for measuring the concentration of a novel therapeutic antibiotic, plazomicin, used to treat complicated urinary tract infections.
Researchers from the University of Queensland (Australia) have discovered a unique biomarker common to multiple cancers that has the potential to change the way early stage cancer is diagnosed.